Share Search
Visit the Share Search
Tissue Regenix extends dCELL technology with new DermaPure product
3rd Oct 2019 08:29
(Sharecast News) - Regenerative medical devices company Tissue Regenix Group announced the launch of a product line extension 'DermaPure Non-Oriented' on Thursday, which it said was specifically tailored for the surgical and trauma markets, further expanding the reach of its flagship 'dCELL' technology product, 'DermaPure'.
The AIM-traded firm said DermaPure Non-Oriented, processed utilising its patented dCELL technology, had two identical sides, meaning the orientation of the graft was not a factor during application or implantation.
That, the board said, would enhance ease of application, while also maintaining the acellular scaffold and thereby promoting tissue regeneration.
The company said the primary indication for the product line would be uro-gynecological procedures, where the group said it already had a "strong" working relationship with partner and specialist distributor, ARMS Medical.
Last week, the product was unveiled at the American Urogynecologic Society annual meeting in Nashville, Tennessee, and was now available for distribution in an initial size of seven by 10 centimetres.
"Our commercial success is predicated on our ability to identify new clinical applications and rapidly develop product lines to meet this demand," said Tissue Regenix interim chief executive officer Gareth Jones.
"Working closely with our strategic partner, ARMS Medical, we are confident that DermaPure Non-Oriented will offer our clinicians the clinical outcomes and health economic benefits they require.
"We continue to see the growing demand for DermaPure, as demonstrated in our recent interim results, and expect that DermaPure Non-Oriented will augment this product portfolio, driving adoption by physicians in the future."
The AIM-traded firm said DermaPure Non-Oriented, processed utilising its patented dCELL technology, had two identical sides, meaning the orientation of the graft was not a factor during application or implantation.
That, the board said, would enhance ease of application, while also maintaining the acellular scaffold and thereby promoting tissue regeneration.
The company said the primary indication for the product line would be uro-gynecological procedures, where the group said it already had a "strong" working relationship with partner and specialist distributor, ARMS Medical.
Last week, the product was unveiled at the American Urogynecologic Society annual meeting in Nashville, Tennessee, and was now available for distribution in an initial size of seven by 10 centimetres.
"Our commercial success is predicated on our ability to identify new clinical applications and rapidly develop product lines to meet this demand," said Tissue Regenix interim chief executive officer Gareth Jones.
"Working closely with our strategic partner, ARMS Medical, we are confident that DermaPure Non-Oriented will offer our clinicians the clinical outcomes and health economic benefits they require.
"We continue to see the growing demand for DermaPure, as demonstrated in our recent interim results, and expect that DermaPure Non-Oriented will augment this product portfolio, driving adoption by physicians in the future."